Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer
Authors
Keywords
Ovarian cancer, FASN, FASN inhibitor, Cerulenin, Biomolecular marker, Cisplatin, Resistance, Chemotherapy, <sup>18</sup> F-fluoromethylcholine, Imaging
Journal
Journal of Translational Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-05-06
DOI
10.1186/s12967-015-0511-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pegylated liposomal doxorubicin in the management of ovarian cancer
- (2014) Nicoletta Staropoli et al. CANCER BIOLOGY & THERAPY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer
- (2014) Yunlang Cai et al. MEDICAL ONCOLOGY
- Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation
- (2014) Karen Bräutigam et al. Translational Oncology
- Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved
- (2013) Avtar Singh Meena et al. PLoS One
- Different fatty acid metabolism effects of (−)-Epigallocatechin-3-Gallate and C75 in Adenocarcinoma lung cancer
- (2012) Joana Relat et al. BMC CANCER
- Inhibition of fatty acid synthase supresses osteosarcoma cell invasion and migration
- (2012) Yong Shu et al. Indian Journal of Pathology and Microbiology
- Metabolic Shifts Induced by Fatty Acid Synthase Inhibitor Orlistat in Non-small Cell Lung Carcinoma Cells Provide Novel Pharmacodynamic Biomarkers for Positron Emission Tomography and Magnetic Resonance Spectroscopy
- (2012) Madhuri Sankaranarayanapillai et al. MOLECULAR IMAGING AND BIOLOGY
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
- (2012) Jaime Prat VIRCHOWS ARCHIV
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Unknown
- (2011) Shahab Uddin et al. MOLECULAR MEDICINE
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
- (2010) Robert J. Kurman et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines
- (2010) Karen Bräutigam et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis
- (2010) Karina G Zecchin et al. LABORATORY INVESTIGATION
- Fatty acid synthase as a novel target for meningioma therapy
- (2010) Daniela Haase et al. NEURO-ONCOLOGY
- Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells
- (2009) Thomas W. Grunt et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling
- (2008) Heather S. Hoover et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started